Australia markets closed

GlucoTrack, Inc. (GCTK)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
2.4000-0.0200 (-0.83%)
At close: 04:00PM EDT
2.4200 +0.02 (+0.83%)
After hours: 06:04PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.4200
Open2.3800
Bid0.0000 x 0
Ask0.0000 x 0
Day's range2.3600 - 2.5200
52-week range0.6650 - 4.9500
Volume14,691
Avg. volume41,677
Market cap13.149M
Beta (5Y monthly)0.13
PE ratio (TTM)N/A
EPS (TTM)-2.1000
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    GLUCOTRACK REPORTS SUCCESSFUL COMPLETION OF FIRST REPORTED LONG-TERM PRECLINICAL STUDY OF ITS EPIDURAL GLUCOSE MONITORING SENSOR

    Completion of the novel epidural continuous glucose monitoring study confirms its potential for providing simplified disease management for patients with painful diabetic neuropathy Rutherford, NJ, June 13, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that its implantable continuous glucose monitor has succ

  • GlobeNewswire

    GLUCOTRACK TO PRESENT IN THE JUNE 2024 SIDOTI SMALL CAP CONFERENCE

    Rutherford, NJ, June 10, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will participate in the Sidoti Small Cap Investor Conference. Paul V. Goode, CEO of Glucotrack, will present on Wednesday, June 12, 2024 at 3:15 PM ET and will hold one-on-one meetings. Interested parties may register using th

  • GlobeNewswire

    GLUCOTRACK ANNOUNCES 90-DAY PRECLINICAL STUDY RESULTS THAT DEMONSTRATE SUSTAINED ACCURACY OF ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR

    Highly accurate continuous blood glucose monitor demonstrates Mean Absolute Relative Difference (MARD) of 4.7% at Day 90 Continuous blood glucose monitor offers the potential for simplified, discreet and less intrusive glucose monitoring for people with diabetes Rutherford, NJ, June 05, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people wi